Interventions Study for the Control of Diabetes Mellitus Type 2 in Obese Women

NCT00262548 Phase 4 COMPLETED

The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.

Details

Lead sponsor	AstraZeneca
Phase	Phase 4
Status	COMPLETED
Enrolment	100
Start date	2005-10

Conditions

• Diabetes Mellitus, Type 2

Interventions

• Rosuvastatin; improvement of lipid profile

Primary outcomes

• Patients will be receiving rosuvastatin/placebo for 6 months
• They will have baseline laboratory parameters taken such as glycemia
• HbA1c (glycosylated hemoglobin), low-density lipoprotein cholesterol (LDL-C), computed tomography (CT), high-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and retaken every 3 months
• Every month, patients will be evaluated at the clinic
• All participants will receive an intervention on diet and physical activity counseling, which will be carefully monitored.

Countries

Mexico